Skip to content
Clinical Trials – home

University Multiprofile Hospital For Active Treatment Saint Georgi EAD

Verified siteinfoFast reply

Bulgaria Ulitsa Perushtitsa 1a, 4002 Plovdiv, Bulgaria

  • 76 trials recruiting
  • Cardiac failure · Arteriosclerosis · Obesity
  • Adults and children

About Specializations

University Multiprofile Hospital For Active Treatment Saint Georgi EAD in Plovdiv, Bulgaria specialises in clinical trials of conditions such as Cardiac failure, Arteriosclerosis, Obesity, Schizophrenia, and other specialisations. This site conducts important research.

Main research areas of the site

Gastroenterology

The medical center is at the forefront of gastroenterology research, focusing on innovative treatments for Ulcerative Colitis and Crohn's Disease. The center's work in this area aims to improve the quality of life for pediatric patients through advanced therapeutic options.

  • Ulcerative Colitis
  • Crohn's Disease

By conducting pivotal studies, the center contributes significantly to understanding the pharmacokinetics of new treatments, paving the way for more effective management of these chronic conditions.

Hematology

Specializing in hematology, the center is renowned for its research on Myelofibrosis and related disorders. The focus is on developing therapies that offer better symptom control and improve patient outcomes.

  • Primary Myelofibrosis
  • Post-Polycythemia Vera Myelofibrosis
  • Post-Essential Thrombocythemia Myelofibrosis

The center's research efforts are instrumental in comparing the efficacy of novel treatments against standard therapies, thus enhancing therapeutic strategies for these complex conditions.

Neurology

In the field of neurology, the center is dedicated to advancing treatments for Multiple Sclerosis. Through rigorous clinical trials, the center evaluates the efficacy of new medications in delaying disease progression and reducing relapse rates.

  • Relapsing Multiple Sclerosis

These studies are crucial in providing insights into the long-term management of neurological disorders, offering hope for improved patient care.

Oncology

The center's oncology department is a leader in researching treatments for various types of lymphoma and leukemia. The focus is on comparing the effectiveness of novel drug combinations to enhance patient survival and quality of life.

  • Follicular Lymphoma
  • Marginal Zone Lymphoma
  • Chronic Lymphocytic Leukemia

By exploring innovative therapeutic approaches, the center plays a pivotal role in the fight against cancer, contributing to the development of more effective treatment protocols.

Endocrinology

In endocrinology, the center focuses on conditions such as short stature in children and Cushing's Syndrome. The research aims to optimize treatment regimens and improve growth outcomes in pediatric patients.

  • Short Stature in Children
  • Cushing's Syndrome

Through comprehensive studies, the center enhances understanding of these conditions, leading to better therapeutic strategies and patient care.

Cardiology

The cardiology department is committed to advancing treatments for heart failure and pulmonary hypertension. The center's research focuses on evaluating new drug efficacy and safety to improve cardiovascular health.

  • Heart Failure with Reduced Ejection Fraction
  • Pulmonary Hypertension

By conducting cutting-edge clinical trials, the center contributes to the development of innovative therapies that address unmet needs in cardiovascular medicine.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease? Our clinical trial advisor will do it for you.

Site location
Ulitsa Perushtitsa 1a4002 PlovdivBulgaria
Recruiting now
76 trials
Conditions studied
138
Partner status
Verified site

More sites in PlovdivBulgaria

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

204 clinical trials

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Phase 2 Study of Nemolizumab for Skin Thickening in Adults with Systemic Sclerosis

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Nemolizumab
  • Sponsor:Galderma S.A.

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Obesity+2

Recruiting

A study to evaluate the effects of zenagamtide on weight and pain in patients with overweight or obesity and knee osteoarthritis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Obesity+2

Recruiting

A study to evaluate the efficacy and safety of zenagamtide in people with overweight or obesity and knee osteoarthritis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Study of sotorasib, panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Bevacizumab
  • Sponsor:Amgen Inc.

Psoriasis

Recruiting

Long-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Colorectal cancer+1

Recruiting

Study of NGM120 in patients with colorectal cancer and cancer cachexia: Evaluating effects on body weight

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:NGM120
  • Sponsor:Ngm Biopharmaceuticals Inc.

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:AstraZeneca AB
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease? Our clinical trial advisor will do it for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.